ABCG2 and neoplasm: By using a preclinical mouse model, we here show that although BRAFV600E‐positive MBMs cause a disruption of BBB integrity, P‐gp and BCRP are expressed in the tumor blood vessels, thereby reducing the efficacy of vemurafenib by limiting its distribution into MBM lesions.